The President of the Office for the Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL) estimates that approximately 20% of all the 10,000 medicinal products registered in Poland will be affected...more
12/20/2018
/ Biosimilars ,
EU ,
Life Sciences ,
Medical Devices ,
Medical Reimbursement ,
Member State ,
No-Deal Brexit ,
Pharmaceutical Industry ,
Poland ,
Regulatory Standards ,
UK ,
UK Brexit
The President of the Office for the Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL) estimates that approximately 20% of all the 10,000 medicinal products registered in Poland will be affected...more